AtriCure’s proven history in the cryoablation market started with the acquisition of the Frigitronics line, which was the Gold Standard of cryoablation devices in the cardiac arrhythmia market for over two decades.
The Frigitronics line has since been improved upon with the development of the cryoICE®, cryoablation probe that is now in its third generation. The third generation provides improved ergonomics and functionality. AtriCure’s cryo devices use nitrous oxide, which has been studied in over 100 medical and scientific papers. Nitrous oxide is the most researched and utilized cryo gas by cardiac surgeons.